Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Ali Al-Attar

Plastic Surgery Alexandria, VA Medical Doctor

NPI 1659529907 CMS profile 302329

4660 Kenmore Ave, Suite 220, Alexandria, VA 22304

Open in the dashboard

General payments

$739

20 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Ali Al-Attar of Alexandria, VA is reported in the CMS Open Payments database as having received $739 across 20 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 30th percentile of Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $141 2
2022 General $42 2
2021 General $192 5
2020 General $133 1
2019 General $231 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ali Al-Attar
  • Plastic Surgery median
  • Middle half of Plastic Surgery
  • National median

In program year 2025, general payments to Ali Al-Attar were reported at $0. Among 3,701 Plastic Surgery profiles paid that year, the median was $379 and the middle half received between $138 and $1,100.

Show as a table
Year Ali Al-Attar Plastic Surgery median Middle half National median
2019 $231 $371 $122–$1,483 $163
2020 $133 $158 $52–$438 $114
2021 $192 $249 $87–$752 $132
2022 $42 $274 $102–$793 $149
2023 $0 $299 $113–$891 $160
2024 $141 $361 $124–$1,062 $164
2025 $0 $379 $138–$1,100 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Allergan Inc. $231 10 payments
  2. Bard Peripheral Vascular, Inc. $192 5 payments
  3. Baxter Healthcare $149 2 payments
  4. Stryker Corporation $121 1 payment
  5. Sientra, Inc. $26 1 payment
  6. Abbott Laboratories $20 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $739 20 payments
Products named General payments · program years 2019–2024
  1. NATRELLE $174 5 payments
  2. No Related Product $133 1 payment
  3. EVEREST SPINAL SYSTEM $121 1 payment
  4. ALLODERM $52 4 payments
  5. SIENTRA HIGH STRENGTH COHESIVE SILICONE GEL BREAST IMPLANT $26 1 payment
  6. I-STAT $20 1 payment
  7. STRATTICE $4 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

45

Median for Plastic and Reconstructive Surgery: 61

Drug cost

$260

Median for Plastic and Reconstructive Surgery: $369

Branded share of claims

0%

Median for Plastic and Reconstructive Surgery: 30%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cephalexin Generic 18 $134
Cefadroxil Generic 12 $73
Fluconazole Generic 15 $53

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,638 Part D prescribers listed as Plastic and Reconstructive Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$44,994

Medicare's payments for the services billed

Medicare patients

98

Average age 75

Services billed

199

70 women, 28 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Cancer 44%
Arthritis 43%
Diabetes 19%
Depression 19%
Osteoporosis 18%
Ischemic heart disease 17%
Chronic kidney disease 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

20 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record